Tools
Tools
Wu, S, Calero-Pérez, P, Villamañan, L, Arias-Ramos, N, Pumarola, M, Ortega Martorell, S, Julià-Sapé, M, Arús, C and Candiota, AP (2020) Anti-tumour immune response in GL261 glioblastoma generated by Temozolamide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images. NMR in Biomedicine, 33 (4). ISSN 0952-3480
|
Text
Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images.pdf - Accepted Version Download (1MB) | Preview |
|
|
Text
Figures.pdf - Supplemental Material Download (1MB) | Preview |
|
|
Text
SupplementaryMaterial.pdf - Supplemental Material Download (2MB) | Preview |
Abstract
Glioblastomas (GB) are brain tumours with poor prognosis even after aggressive therapy. Improvements in both therapeutic and follow-up strategies are urgently needed. In previous work we described an oscillatory pattern of response to Temozolomide (TMZ) using a standard administration protocol, detected through MRSI-based machine learning approaches. In the present work, we have introduced the Immune-Enhancing Metronomic Schedule (IMS) with an every 6-days TMZ administration at 60mg/kg, and investigated the consistence of such oscillatory behaviour.
A total of n=17 GL261 GB tumour-bearing C57BL/6j mice were studied with MRI/MRSI every 2 days, and the oscillatory behaviour (6.2±1.5 days period from the TMZ administration day) was confirmed during response. Furthermore, IMS-TMZ produced significant improvement in mice survival (22.5±3.0 days for controls vs 135.8±78.2 for TMZ-treated), outperforming standard TMZ treatment.
Histopathological correlation was investigated in selected tumour samples (n=6) analyzing control and responding fields. Significant differences were found for CD3+ cells (lymphocytes, 3.3±2.5 vs 4.8±2.9 respectively) and Iba-1 immunostained area (microglia/macrophages, 16.8±9.7% and 21.9±11.4% respectively).
Unexpectedly, during IMS-TMZ treatment, tumours from some mice (n=6) fully regressed and remained undetectable without further treatment for one month. These animals were considered “cured” and a GL261 re-challenge experiment performed, with no tumour reappearance in 5 out of 6 cases.
Heterogeneous therapy response outcomes were detected in tumour-bearing mice, and a selected group was investigated (n=3 non-responders, n=6 relapsing tumours, n=3 controls). PD-L1 content was found ca. 3-fold increased in the relapsing group when comparing with control and non-responding groups, suggesting that increased lymphocyte inhibition could be associated to IMS-TMZ failure. Overall, data suggest that host immune response has a relevant paper in therapy response/escape in GL261 tumours under IMS-TMZ therapy. This is associated to changes in the metabolomics pattern, oscillating every 6 days, in agreement with immune cycle length, which is being sampled by MRSI-derived nosological images.
| Item Type: | Article |
|---|---|
| Additional Information: | This is the peer reviewed version of the following article: Wu, S, Calero‐Pérez, P, Villamañan, L, et al. Anti‐tumour immune response in GL261 glioblastoma generated by Temozolomide Immune‐Enhancing Metronomic Schedule monitored with MRSI‐based nosological images. NMR in Biomedicine. 2020;e4229 which has been published in final form at https://doi.org/10.1002/nbm.4229. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. |
| Uncontrolled Keywords: | 1103 Clinical Sciences, 0304 Medicinal and Biomolecular Chemistry, 0903 Biomedical Engineering |
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
| Divisions: | Applied Mathematics (merged with Comp Sci 10 Aug 20) |
| Publisher: | Wiley |
| Date Deposited: | 07 Nov 2019 11:52 |
| Last Modified: | 04 Sep 2021 08:31 |
| DOI or ID number: | 10.1002/nbm.4229 |
| URI: | https://researchonline.ljmu.ac.uk/id/eprint/11715 |
 |
View Item |